Actively Recruiting
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Led by Celgene · Updated on 2026-04-17
224
Participants Needed
42
Research Sites
376 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 and/or CC-99282 and R-CHOP-21 combination has been defined.
CONDITIONS
Official Title
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be 18 years or older at the time of consent
- Histologically confirmed diagnosis of de novo, previously untreated aggressive B-cell lymphoma
- International Prognostic Index (IPI) score 0-5 in Part 1 and IPI 2-5 in Part 2
- Measurable disease with at least one FDG-avid lesion or bi-dimensionally measurable disease by CT or MRI
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Adequate laboratory values including neutrophil count, hemoglobin, platelets, liver enzymes, bilirubin, and creatinine clearance
- Understanding and agreement to follow the Pregnancy Prevention Program for study drugs
- Females of childbearing potential must have two negative pregnancy tests before starting therapy
- Male participants must practice true abstinence or use a condom during sexual contact with pregnant females or females of childbearing potential
You will not qualify if you...
- Significant medical conditions, active infections including COVID-19, or psychiatric illnesses preventing study participation
- Conditions or laboratory abnormalities placing participant at unacceptable risk
- Other lymphoma subtypes besides aggressive B-cell lymphoma
- Documented or suspected central nervous system involvement by lymphoma
- Persistent diarrhea or malabsorption grade 2 or higher despite treatment
- Peripheral neuropathy grade 2 or higher
- History of progressive multifocal leukoencephalopathy
- Chronic systemic immunosuppressive therapy or corticosteroids
- Impaired cardiac function or significant cardiac disease including LVEF below 45%
- Major surgery within 2 weeks before starting study drugs without full recovery
- Inability to swallow tablets
- Known HIV infection
- Known chronic active hepatitis B or C infection
- History of other malignancy unless disease-free for 3 years, with some exceptions
- Hypersensitivity to study drugs or related compounds
- Known allergy to thalidomide, pomalidomide, or lenalidomide
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 42 locations
1
Local Institution - 162
Birmingham, Alabama, United States, 35233
Not Yet Recruiting
2
Mayo Clinic - Arizona
Scottsdale, Arizona, United States, 85259
Actively Recruiting
3
Local Institution - 169
Duarte, California, United States, 91010
Not Yet Recruiting
4
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States, 32224
Withdrawn
5
Mayo Clinic Jacksonville - PPDS
Jacksonville, Florida, United States, 32224
Actively Recruiting
6
Local Institution - 161
Marietta, Georgia, United States, 30060
Not Yet Recruiting
7
University Of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Actively Recruiting
8
Cancer Center Of Kansas-Wichita
Wichita, Kansas, United States, 67214
Actively Recruiting
9
Mayo Clinic - Rochester
Rochester, Minnesota, United States, 55905-0001
Actively Recruiting
10
HealthPartners Cancer Research Center
Saint Louis Park, Minnesota, United States, 55426
Actively Recruiting
11
University of Nebraska - Fred and Pamela Buffet Center
Omaha, Nebraska, United States, 68198
Actively Recruiting
12
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Withdrawn
13
Local Institution - 170
Charlotte, North Carolina, United States, 28204
Not Yet Recruiting
14
MD Anderson Cancer Center
Houston, Texas, United States, 77003
Actively Recruiting
15
Local Institution - 168
Murray, Utah, United States, 84107
Not Yet Recruiting
16
Local Institution - 171
St. George, Utah, United States, 84790
Not Yet Recruiting
17
Local Institution - 501
Adelaide, South Australia, Australia, 5000
Completed
18
Local Institution - 503
Perth, Australia, WA 6000
Completed
19
Local Institution - 502
Waratah, Australia, NSW
Withdrawn
20
Evangelismos General Hospital of Athens
Athens, Greece, 10676
Actively Recruiting
21
General Hospital of Athens "Laiko"
Athens, Greece, 11 527
Actively Recruiting
22
Attikon University General Hospital
Athens, Greece, 12464
Actively Recruiting
23
Local Institution - 703
Pátrai, Greece, 26500
Withdrawn
24
Georgios Papanikolaou General Hospital of Thessaloniki
Thessaloniki, Greece, 57010
Actively Recruiting
25
AIDPORT Sp. z o.o.
Skórzewo, Greater Poland Voivodeship, Poland, 60-185
Actively Recruiting
26
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland, 80-952
Actively Recruiting
27
MCM Krakow - PRATIA - PPDS
Krakow, Poland, 30-727
Actively Recruiting
28
Local Institution - 0706
Poznan, Poland, 60-185
Withdrawn
29
Local Institution - UNK0706
Poznan, Poland, 60-185
Withdrawn
30
SP ZOZ Szpital Uniwersytecki w Krakowie
Słomniki, Poland, 32-090
Actively Recruiting
31
Local Institution - 602
Warsaw, Poland, 02-781
Actively Recruiting
32
Local Institution - 604
Wroclaw, Poland, 50-367
Completed
33
Local Institution - 300
Seoul, South Korea, 06351
Completed
34
Local Institution - 302
Seoul, South Korea, 138-736
Completed
35
Local Institution - 301
Seoul, South Korea, 3080
Completed
36
Hospital Universitari Germans Trias i Pujol ICO Badalona
Barcelona, Spain, 08916
Actively Recruiting
37
Local Institution - 204
Madrid, Spain, 28028
Withdrawn
38
H. Virgen de la Victoria
Málaga, Spain, 29010
Actively Recruiting
39
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
Salamanca, Spain, 37007
Actively Recruiting
40
China Medical University Hospital
Taichung, Taiwan, 40447
Actively Recruiting
41
Taichung Veterans General Hospital
Taichung, Taiwan, 407
Actively Recruiting
42
National Taiwan University Hospital
Taipei, Taiwan, 100229
Actively Recruiting
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
F
First line of the email MUST contain NCT # and Site #.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here